GICS Sector : Healthcare
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies.It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
3 Potential Mid-Cap Biotech Buyout Targets In 2026
Dec -03
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
Nov -19
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
Nov -14
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates
Nov -11
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
Nov -10
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
Oct -31
Pharmaceutical Stocks To Keep An Eye On – October 28th
Oct -30
Top Medical Stocks To Research – October 28th
Oct -30
Avidity Biosciences' Antibody Oligonucleotide Conjugates' 12.05% growth is driven by increasing adoption in targeted therapies, rising demand for precision medicine, and advancements in RNA-based treatments. Strong partnerships, expanding pipeline, and growing investments in gene therapy research also contribute to this growth.
AOC 1001 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases.
AOC 1020 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases.
AOC 1044 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases.
AOC 1067 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases.
Avidity Biosciences, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Avidity Biosciences, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.
Avidity Biosciences, Inc. relies on a few key suppliers for raw materials and equipment. While the company has some bargaining power due to its size and reputation, the suppliers still have some leverage due to the specialized nature of the products.
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory frameworks, and the need for specialized expertise. These barriers make it difficult for new entrants to compete with established companies like Avidity Biosciences, Inc.
The biotechnology industry is highly competitive, with many established companies competing for market share. Avidity Biosciences, Inc. faces intense competition from companies with similar products and technologies, which can lead to pricing pressure and reduced market share.
| Value | |
|---|---|
| Debt Weight | 1.93% |
| Debt Cost | 3.95% |
| Equity Weight | 98.07% |
| Equity Cost | 7.87% |
| WACC | 7.80% |
| Leverage | 1.97% |
Value: 6.0
Growth: 7.1
Quality: 5.2
Yield: 0.0
Momentum: 9.0
Volatility: 4.0
1-Year Total Return ->
Value: 6.2
Growth: 4.4
Quality: 5.0
Yield: 0.0
Momentum: 9.5
Volatility: 5.3
1-Year Total Return ->
Value: 6.7
Growth: 4.1
Quality: 7.2
Yield: 0.0
Momentum: 4.0
Volatility: 4.3
1-Year Total Return ->
Value: 6.4
Growth: 7.9
Quality: 4.2
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->
Value: 6.2
Growth: 2.7
Quality: 5.1
Yield: 0.0
Momentum: 4.0
Volatility: 1.0
1-Year Total Return ->
Value: 6.4
Growth: 1.1
Quality: 3.9
Yield: 0.0
Momentum: 1.0
Volatility: 2.7
1-Year Total Return ->